Drug intelligence / Profile preview

Equine Rabies Immunoglobulin

Development stage: Unknown
Lead developer: Bharat Serums and Vaccines
Modality: Antibody-Based Therapeutics
Administration: Infiltration, Intramuscular

Overview

Equine rabies immunoglobulin is used for post-exposure prophylaxis (PEP) against rabies. It is derived from the plasma of horses immunized with rabies vaccine and is administered to neutralize the rabies virus at the wound site. It provides temporary passive immunity until the body can produce its own antibodies. ERIG is often used in developing countries due to its lower cost compared to human rabies immunoglobulin (HRIG).

Brand names: favirab
Other names: Equine Rabies Immune Globulin (ERIG)

Targets

RABV-G (Rabies virus glycoprotein)

Beyond the preview

Go deeper on Equine Rabies Immunoglobulin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Equine Rabies Immunoglobulin.

Explore the full profile